Invex Therapeutics (ASX:IXC) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:IXC Invex Therapeutics Ltd ASX:IXC
35 GF Score
Price A$0.11
! 1 Warning Sign
View Full Analysis

What is Invex Therapeutics FFO per Share?

FFO per Share only applies to REITs.

ASX:IXC
35GF Score
Invex Therapeutics Ltd ASX:IXC
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
35GF Score

Get the complete analysis for ASX:IXC

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price